Clinical trial
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in…
NCT00124241 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00124241 |
|---|---|
| Title | An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B |
| Official title | A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003 |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | telbivudine, lamivudine |
| Primary completion | Feb 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Jul 27, 2005 |
| Last update posted | May 12, 2015 |
| Countries | Canada, China, France, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: